Abstract
Hypertrophic cardiomyopathy (HCM) is a remarkably heterogeneous disease comprised of numerous subgroups of patients. Although HCM is not a uniformly progressive illness, the symptoms may occur or worsen at virtually any age, most frequently in midlife.
HCM has now transformed into a contemporary, highly treatable condition with effective options that alter natural history along specific adverse pathways.